Pancreatic Cancer Research

ResearcherHumboldt-Universität zu BerlinActive in the last 2 years

Hendrik Seeliger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5937-052X; OpenAlex author ID A5072222636. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 11

  1. Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Last author DOI 10.1007/s13402-025-01128-8↗
  2. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Last author DOI 10.1007/s00432-022-04518-9↗
  3. Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer. Co-author DOI 10.3390/cancers15020456↗
  4. Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma. Last author DOI 10.1007/s00411-022-00962-w↗
  5. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Last author DOI 10.1007/s13402-020-00559-9↗
  6. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  7. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00432-018-2717-2↗
  8. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-018-4973-6↗
  9. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-017-2351-4↗
  10. Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. Co-author DOI 10.1371/journal.pone.0056760↗
  11. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. First author DOI 10.1111/j.1582-4934.2011.01473.x↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ioannis Pozios · 8 shared papers, 2017–2025 · strength 1.10
  2. Christiane J. Bruns · 9 shared papers, 2012–2025 · strength 0.98
  3. Nina A. Hering · 4 shared papers, 2021–2025 · strength 0.72
  4. Katharina Beyer · 4 shared papers, 2021–2023 · strength 0.60
  5. Lucas D. Lee · 3 shared papers, 2021–2025 · strength 0.51
  6. Peter Čamaj · 3 shared papers, 2017–2025 · strength 0.42
  7. Thomas Knösel · 4 shared papers, 2017–2023 · strength 0.40
  8. Georgios Antonios Margonis · 2 shared papers, 2021–2023 · strength 0.27
  9. Carsten Kamphues · 2 shared papers, 2021–2022 · strength 0.24
  10. Yue Zhao · 3 shared papers, 2017–2018 · strength 0.23
  11. Jin Peng He · 1 shared paper, 2021 · strength 0.09
  12. Alessandra Pulvirenti · 1 shared paper, 2021 · strength 0.09
  13. Dimitris Bertsimas Ioannis · 1 shared paper, 2021 · strength 0.09
  14. Hideo Baba · 1 shared paper, 2021 · strength 0.09
  15. Michael Ian D'Angelica · 1 shared paper, 2021 · strength 0.09
  16. Jacob L. van Dam · 1 shared paper, 2021 · strength 0.09
  17. Caitlin A. McIntyre · 1 shared paper, 2021 · strength 0.09
  18. Alessandro Zerbi · 1 shared paper, 2021 · strength 0.09
  19. Katsunori Imai · 1 shared paper, 2021 · strength 0.09
  20. Bas Groot Koerkamp · 1 shared paper, 2021 · strength 0.09
  21. Peter Kornprat · 1 shared paper, 2021 · strength 0.09
  22. Francesca Gavazzi · 1 shared paper, 2021 · strength 0.09
  23. Christopher Lee Wolfgang · 1 shared paper, 2021 · strength 0.09
  24. Matthew John Weiss · 1 shared paper, 2021 · strength 0.09
  25. Alice Chia-Chi Wei · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.